Catching Hepatitis: Why Merck (MRK) Was Willing to Break the Bank for Idenix (IDIX)
Sovaldi Has Demonstrated Treating Hepatitis C is a Good Business to Be In
Idenix has zero, count ‘em, zero therapies that are currently commercially available and had zero, count ‘em, zero dollars in revenue last year. So why the massive price tag for a company whose most-advanced therapy has only reached Phase II clinical trials? Because the company’s primary focus is treating hepatitis C, a market that has grown astonishingly lucrative and is getting astonishingly competitive as a result. ISI Group analyst Mark Schoenebaum said in a research note the price paid by Merck would place the global hepatitis C market at $20 billion by 2018, and everyone's now fighting to secure their piece.The first inklings that this would be the case came when Gilead Sciences (GILD) announced that Sovaldi, the first truly effective hepatitis C treatment to hit the market, would cost $84,000 for a round of treatment, better than $1,000 a pill.
This created waves. Big ones. Henry Waxman fired off a strongly-worded letter to Gilead CEO Dr. John C. Martin ...
=========================
http://www.forbes.com/lists/2012/12/ceo-compensation-12_John-C-Martin_A1XN.html
http://www.forbes.com/pictures/eggh45jef/john-c-martin-of-gilead-sciences/
Click photos for larger size
John Hammergreen, McKesson Medical Supplies
====================================================================
VA puts Gilead's $1,000-a-pill hepatitis C drug on its list of meds
=========================
http://www.fiercepharma.com/story/activists-pounce-1000-day-price-gileads-hep-c-wonder-drug-sovaldi/2013-12-09
Activists pounce on $1,000-a-day price for Gilead's hep C wonder drug, Sovaldi
=========================
Is this Gilead's Biggest Risk?
Motley Fool - 22 minutes ago
In fact, Sovaldi poses a huge riddle for Gilead. How can a $1,000
pill designed overwhelmingly for those who are low-income, or live in
low- income countries, become accessible to the patients who need it
most? In the United States, more than half of the ... In the near term, Gilead faces a risk doctors may choose to wait to treat hepatitis C patients until later in 2014, when the fixed-dose combination Sovaldi + Ledipasvir becomes available. At the very least, the need to find all those new patients each quarter will make ...
AHF Supports AHIP's Labeling of Sovaldi Pricing as “Unsustainable,” Reaffirms ...
MarketWatch - Jun 12, 2014
WASHINGTON, Jun 12, 2014 (BUSINESS WIRE) -- In a series of letters to
be sent to state Medicaid directors this week, AIDS Healthcare
Foundation (AHF) President Michael Weinstein will ask the state
directors to block Gilead Sciences' new $1,000-per-pill ...
Govt urged to make new hepatitis drug affordable
DAWN.com - 20 hours ago
Sovaldi, whose developer, Gilead,
an American pharmaceutical company, is expected to earn $9.1 billion by
2017, was recently registered by the US Food and Drug Administration.
However, it has yet to be registered in Pakistan. ... According to
Professor Najib, the cost of Sovadi is $1,000 per tablet in the
US and that the high price forced local insurance companies to have
reservations about its coverage in the health insurance schemes and
thus, restricting its prescription. “Unfortunately, the laws of the
potency of ...
Health:
No sofosbuvir patent in Egypt, but Gilead deal still expensive
Cairo,
8 April (Heba Wanis*) – Preliminary examination of the patent application
on sofosbuvir, a major hepatitis C medicine, at the Egyptian Patent
Office showed that it is unlikely to be patented.
India’s pro-consumer patent regime is an exciting alternative to the dominant IP model pushed by the US
Gilead’s Sovaldi is a wonder drug
sold at a shocker price. It is the most effective cure for Hepatitis C,
and is in high demand. But the drug has caused an outrage in the US
where patients, healthcare providers and insurers have questioned its
exorbitant price tag. For a 12-week course, Sovaldi costs $84,000
(₹50,00,000).
Sovaldi was also in the news for an
entirely different set of reasons. Earlier this month, an Indian generic
firm, Natco, filed a ‘pre-grant opposition’ to Gilead’s patent covering
Sovaldi. The move could result in the Indian Patent Office rejecting
Gilead’s patent, bringing down the price to a fraction of its current
price.
This is not a one-off incident. India has
tackled the issue of unaffordable prices of drugs protected by patents
by incorporating a remarkable array of provisions into its intellectual
property (IP) law.
These provisions qualify as
‘legitimate flexibilities’ allowed under the WTO’s Trade Related aspects
of Intellectual Property Rights (TRIPS) Agreement. ...
At $1000 per pill, Gilead's hepatitis C drug has insurers, others ...
San Francisco Business Times (blog)-
Drug manufacturer Gilead Sciences defends the price tag on grounds ... over a 10-to-30-year span, leading to cirrhosis, liver failure and death. ...
Hepatitis C drugs show promise, but price is too high for most patients
CTV News-
In an email to CTV News, Gilead, the makers of Sovaldi, said that the ... sugar-coat her reality: "I am stage 4, the next step is death," she said.
http://hepc-cured.com/ you know there is a cure for Hepatitis C but we may never see it?
- Over 170 million people worldwide have the virus, 4 million people in the U.S.
- Hepatitis C (HCV) now kills more people than AIDS
- Liver Cancer due to Hepatitis C is the most rapidly increasing cause of cancer death in the U.S.
- HCV is the number one reason for liver transplants
- 3-4% of adults are chronically infected
Act NOW and sign the petition to pressure Gilead Sciences to work with Bristol-Myers on the Phase III drug trials necessary to get the cure to market.
1980 Forest View Avenue
Hillsborough, CA 94010
Find on map >>
Show street view
Owner: JOHN C MARTIN & ROSEMARY C MARTIN
Land value: $1,671,831
Building value: $1,671,831
Total value for property: $3,343,662
Assessments for tax year: 2009
Last sale: $2,650,000
Date of last sale: 06/13/1997
Hillsborough, CA 94010
Find on map >>
Show street view
Owner: JOHN C MARTIN & ROSEMARY C MARTIN
Land value: $1,671,831
Building value: $1,671,831
Total value for property: $3,343,662
Assessments for tax year: 2009
Last sale: $2,650,000
Date of last sale: 06/13/1997
Rosemary Martin - $7,600 in Political Contributions for 2004
www.campaignmoney.com/political/contributions/rosemary-martin.asp?...HILLSBOROUGH, CA 94010, None/None, $5,000, 07/12/2004, P, GILEAD SCIENCES INC HEALTHCARE POLICY PAC · Martin, Rosemary A Mrs. PEARLAND ...Rosemary Martin - $5,000 in Political Contributions for 2006
www.campaignmoney.com/political/contributions/rosemary-martin.asp?...... Contibuted To. Martin, Rosemary HILLSBOROUGH, CA 94010, Homemaker, $5,000, 01/11/2006, P, GILEAD SCIENCES INC HEALTHCARE POLICY PAC ...HILLSBOROUGH, California (CA) Political Contributions by ...
www.city-data.com/elec2/.../elec-HILLSBOROUGH-CA-06.ht...Latest news about elections in HILLSBOROUGH, CA collected exclusively by ...... Rosemary Martin (Homemaker), (Zip code: 94010) $5000 to GILEAD ...
City‑DataHILLSBOROUGH, California (CA) Political Contributions by ...
www.city-data.com/elec/elec-HILLSBOROUGH-CA.htmlFCC Registered Amateur Radio Licenses in city_name, California. ... Rosemary Martin (None/None), (Zip code: 94010) $5000 to GILEAD SCIENCES INC ...
City‑DataJacksonville.com: **Obituaries** - Florida Times-Union
jacksonville.com/.../1000_21_November_200...Nov 21, 2000 - She is survived by her husband, Dr. Tellis A. Martin; four children; Dr. John C. (
The Florida Times‑UnionRosemary) Martin of Hillsborough, CA, Carolyn L. (Thomas) ...
MARTIN - Janet Sacks Martin, 72, passed away on Saturday, November 18, 2000. She was born on January 11, 1928 in Philadelphia, PA. She graduated from Ursinus College in Collegeville, PA with a B. S. in Chemistry in 1949. Jan moved with her family to Evansville, Indiana in 1953. After graduating from the University of Evansville with a Masters in Education, she taught chemistry, physics and computer literacy at the Evansville Day School for move than twenty years. She relocated to Isle of Palms, SC after retirement in 1987 where she was an elder of the Sunrise Presbyterian Church, and active in the Garden Club, the Newcomers Club, the Literacy Program of Charleston and was a volunteer Medicare claims filer. In 1996 she moved to Penny Retirement Community in Penny Farms, FL, but continued to Summer in Isle of Palms. At PRC, she was Treasurer of the PRC Association and a volunteer AARP tax preparer. Jan will be remembered as a loving daughter, wife, mother and grandmother, an excellent bridge player and a good and generous friend to many. She is survived by her husband, Dr. Tellis A. Martin; four children; Dr. John C. (Rosemary) Martin of Hillsborough, CA, Carolyn L. (Thomas) Marino of New York City, Dr. Robert Sacks (Rebecca) Martin of Pacific Palisades, CA and Thomas E. (Sue Ann) Martin, CPA of Concord, NJ; and seven grandchildren, John, Margaret Rose, Noah, Rachel, Chelsea, Kelly and Robert. A Graveside memorial service will be held at 10:'30 Am on Saturday, December 2, at Penny Farms Cemetery. Memorial donations in Janets memory may be made to Penny Retirement Community, Janet Martin Memorial Fund, Box 555, Penny Farms, FL 32079.
http://www.concordmonitor.com/news/4719029-95/ann-sue-savage-concord
Sue Ann Martin
For the Monitor, Saturday, April 10, 2010
... Sue Ann is survived by her husband, Thomas E. Martin; and her three children Chelsea Margaret, Kelly Marie and Robert Tellis; her mother, Barbara Savage-Fraser; and her step-father, John Fraser of Concord; her three brothers, Thomas Savage of Silver Springs, Md.; Douglas Savage of Bel Mar, Calif.; and William Savage of Ashland, Mass. ...
http://issuu.com/universityofvermont/docs/commencement2007
Martin is currently the Chairman and CEO of Gilead Sciences, where he has worked for 23 years (he has been the CEO for 17 years). The 61-year-old Martin holds a PhD in organic chemistry from the
University of Chicago and an MBA in marketing from Golden Gate
University.
http://www.chi.org/leadership/board-of-directors/john-c-martin-ph-d/
... Sue Ann is survived by her husband, Thomas E. Martin; and her three children Chelsea Margaret, Kelly Marie and Robert Tellis; her mother, Barbara Savage-Fraser; and her step-father, John Fraser of Concord; her three brothers, Thomas Savage of Silver Springs, Md.; Douglas Savage of Bel Mar, Calif.; and William Savage of Ashland, Mass. ...
http://issuu.com/universityofvermont/docs/commencement2007
203rd Commencement Ceremony - publishing
issuu.com/universityofvermont/docs/commencement2007
... Newport Jenessa Danielle Mahoney, Hampstead, NH Chelsea Margaret Martin, Concord, NH Coleen May McCann, Trumbull, CT Rebecca Ann McCormick, ...John Martin - Golden Gate University
www.ggu.edu/press-room/profiles/.../john-martin
Under the visionary leadership of President and CEO John Martin, Gilead Sciences produced its first profit in 2002 earned both sales of $3 billion and the ...
Golden Gate University
The Wealthiest Person In Every US State - Business Insider
www.businessinsider.com/the-wealthiest-person-in-every...
Business Insider, Oct 30, 2013
WYOMING: John C. Martin is worth $300 million
John C. Martin, Ph.D., joined Gilead Sciences in 1990 and
currently serves as chairman of the board of directors and CEO. Prior to
joining Gilead, Martin held several leadership positions at
Bristol-Myers Squibb and Syntex Corp.Martin has served as president of the International Society for Antiviral Research, chairman of the board of directors of BayBio and chairman of the California Healthcare Institute. He also served on the National Institute of Allergy & Infectious Diseases Council, on the board of directors of the Biotechnology Industry Organization (BIO), on the board of trustees of the University of Chicago and on the board of trustees of the Golden Gate University. Additionally, Martin served on the Centers for Disease Control/Health Resources and Services Administrations Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS. He is currently a member of the board at Gen-Probe Inc. He has been a member of the board of directors of CHI since 2003 and previously served as chairman of the board from 2005 to 2006 and 2009.
Hosea 6:8:
"Gilead is a city of those who work iniquity; it is stained with blood."
Chelsea Martin in Concord, NH
| Age 27
Current Addresss:
Current Phone:
Possible Relatives
Thomas Martin in Concord, NH
Thomas E Martin in Concord, NH
| Age 56
Current Phone:
Mary Martin in Concord, NH
| Age 29
Sue Ann Martin in Concord, NH
| Age 54
Current Phone:
-
John C. Martin, PhD
Chairman and Chief Executive Officer, Gilead Sciences
-
John F. Cogan, PhD
Lead Independent Director, Gilead Sciences
-
Etienne F. Davignon
Minister of State for Belgium, Chairman, Genfina
-
Carla A. Hills
Chair and Chief Executive Officer, Hills & Company, International Consultants
-
Kevin E. Lofton
President and Chief Executive Officer, Catholic Health Initiatives
-
John W. Madigan
Retired Chairman and Chief Executive Officer, Tribune Company
-
Nicholas G. Moore
Retired Global Chairman, PricewaterhouseCoopers
-
George P. Shultz, PhD
Director Emeritus, Gilead Sciences
-
Richard J. Whitley, MD
Distinguished Professor, Loeb Scholar Chair in Pediatrics, Professor of Pediatrics, Microbiology, Medicine, and Neurosurgery, University of Alabama at Birmingham
-
Gayle Edlund Wilson
Immediate Past Chair, Ralph M. Parsons Foundation
-
Per Wold-Olsen
Retired President, Human Health Intercontinental Division, Merck & Co., Inc.
No comments:
Post a Comment